Шутки в сторону: банковские счета Евгения Петросяна арестованы 7days.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 7days.ru Daily Mail and Mail on Sunday newspapers.
The Lancet Respiratory Medicine: COVID-19 causes more severe disease than seasonal influenza, comparison of data from over 130,000 hospitalised patients confirms
Peer-reviewed / Observational / People
Study based on French national data from 89,530 patients hospitalised with COVID-19 between 1 March and 30 April 2020 and 45,819 patients hospitalised with seasonal influenza between 1 December 2018 - 28 February 2019.
Death rate among hospitalised COVID-19 patients was three times higher than seasonal influenza (15,104/89,530 [16.9%] vs influenza 2640/45,819 [5.8%]).
More patients with COVID-19 required intensive care (14,585/89,530 [16.3%] vs influenza, 4926/45,819 [10.8%]) and the average stay in ICU with COVID-19 was nearly twice as long (15 days vs 8 days)
Fewer children aged under 18 years were hospitalised with COVID-19 compared with seasonal influenza (1227/89,530 [1.4%] vs 8942/45,819 [19.5%]), but a larger proportion of those aged under 5 years required intensive ca
Peer-reviewed / Observational / People
Study based on French national data from 89,530 patients hospitalised with COVID-19 between 1 March and 30 April 2020 and 45,819 patients hospitalised with seasonal influenza between 1 December 2018 - 28 February 2019.
Death rate among hospitalised COVID-19 patients was three times higher than seasonal influenza (15,104/89,530 [16.9%] vs influenza 2640/45,819 [5.8%]).
More patients with COVID-19 required intensive care (14,585/89,530 [16.3%] vs influenza, 4926/45,819 [10.8%]) and the average stay in ICU with COVID-19 was nearly twice as long (15 days vs 8 days)
Fewer children aged under 18 years were hospitalised with COVID-19 compared with seasonal influenza (1227/89,530 [1.4%] vs 8942/45,819 [19.5%]), but a larger proportion of those aged under 5 years required intensive care for COVID-19 (14/ 613 [2·3%] vs influenza 65/ 6973 [0·9%]). The case fatality rate in children under 5 years was similar for both groups and was very low (number
Search jobs 18-Dec-2020 Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines with Potential to Eliminate Cold Chain and Transform Global Vaccination Logistics for COVID-19
OXFORD, England and LONDON, Dec. 18, 2020 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London ( Imperial ), to develop RNA vaccines, including against SARS-CoV-2, that are stable at ambient temperatures and up to 40
o Celsius (104
o Fahrenheit).
(1)
OXFORD, England and LONDON, Dec. 18, 2020 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London ( Imperial ), to develop RNA vaccines, including against SARS-CoV-2, that are stable at ambient temperatures and up to 40
o Celsius (104
o Fahrenheit).
The ability to create such vaccines could minimize or eliminate the cold chain requirements for global deployment and mass vaccination programmes with RNA-based vaccines.
The collaboration will investigate the potential of combining Enesi s ImplaVax technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial s self-amplifying RNA (saRNA) technology and novel Polyplex DNA/RNA stabil